Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A plasma cell neoplasm that is resistant to treatment.
No clinical trials have been registered for refractory plasma cell neoplasm.
3 publications have been identified in PubMed for refractory plasma cell neoplasm. Research spans Case Report / Case Series (100%).
Cox MC (2026). [PMID: 41847400](https://pubmed.ncbi.nlm.nih.gov/41847400/). *Clinical hematology international*. [Case Report / Case Series]
El Maachi N (2025). [PMID: 40539163](https://pubmed.ncbi.nlm.nih.gov/40539163/). *Cureus*. [Case Report / Case Series]
Sweidan HB (2024). [PMID: 39403422](https://pubmed.ncbi.nlm.nih.gov/39403422/). *Cureus*. [Case Report / Case Series]
Data assembled from 2 of 12 sources · Last updated Sep 20, 2026, 8:21 AM UTC
AI-curated news mentioning refractory plasma cell neoplasm
Updated May 21, 2026
Recent research provides new insights into the role of clonotypic B cells in plasma cell neoplasia, potentially influencing future therapeutic strategies. Understanding these mechanisms could lead to improved treatment options for affected patients.